Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/24/2025 | $80.00 | Neutral → Overweight | Piper Sandler |
| 1/30/2025 | $75.00 → $90.00 | Hold → Buy | Stifel |
| 1/16/2025 | $60.00 | Peer Perform → Underperform | Wolfe Research |
| 12/16/2024 | Neutral → Buy | BofA Securities | |
| 10/11/2024 | $70.00 | Equal-Weight | Morgan Stanley |
| 9/18/2024 | $85.00 → $70.00 | Buy → Hold | Jefferies |
| 7/31/2024 | Neutral → Outperform | Daiwa Securities | |
| 7/29/2024 | Underperform → Peer Perform | Wolfe Research |
SD - Edwards Lifesciences Corp (0001099800) (Filer)
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
10-Q - Edwards Lifesciences Corp (0001099800) (Filer)
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00
Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously
Wolfe Research downgraded Edwards Lifesciences from Peer Perform to Underperform and set a new price target of $60.00
Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre
IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presented results of two practice-changing FDA clinical trials, EARLY TAVR and TRISCEND II Reiterating 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50 Continuing to expect mid-year asymp
Edwards Lifesciences (NYSE:EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Prompt intervention for severe AS patients before symptoms developed resulted in: Significantly lower costs for the healthcare system at 1 year ($36,000 less per patient); Shorter length of stay during their treatm
Edwards Lifesciences (NYSE:EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p
Transforming Care for Severe AS Patients Edwards Lifesciences (NYSE:EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance (watchful waiting). Wit